Tango Therapeutics Inc (TNGX) - Total Assets
Based on the latest financial reports, Tango Therapeutics Inc (TNGX) holds total assets worth $398.69 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check TNGX cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Tango Therapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Tango Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check Tango Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Tango Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tango Therapeutics Inc's total assets of $398.69 Million consist of 88.7% current assets and 11.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Tango Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Tango Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tango Therapeutics Inc's current assets represent 88.7% of total assets in 2025, an increase from 74.7% in 2019.
- Cash Position: Cash and equivalents constituted 28.2% of total assets in 2025, down from 41.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tango Therapeutics Inc Competitors by Total Assets
Key competitors of Tango Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
Tango Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.32 | 6.98 | 5.71 |
| Quick Ratio | 16.32 | 6.98 | 5.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $332.08 Million | $228.17 Million | $173.50 Million |
Tango Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Tango Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.59 |
| Latest Market Cap to Assets Ratio | 8.49 |
| Asset Growth Rate (YoY) | 26.0% |
| Total Assets | $398.69 Million |
| Market Capitalization | $3.39 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Tango Therapeutics Inc's assets at a significant premium (8.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Tango Therapeutics Inc's assets grew by 26.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tango Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Tango Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $398.69 Million | +25.97% |
| 2024-12-31 | $316.49 Million | -21.38% |
| 2023-12-31 | $402.57 Million | -7.77% |
| 2022-12-31 | $436.47 Million | -12.73% |
| 2021-12-31 | $500.15 Million | +141.33% |
| 2020-12-31 | $207.25 Million | +271.66% |
| 2019-12-31 | $55.76 Million | -- |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more